What is Trinity Biotech?
Trinity Biotech operates as a commercial-stage biotechnology enterprise specializing in the development, manufacturing, and global distribution of diagnostic systems. Its core competencies span infectious disease detection and the quantification of critical chemistry parameters, including Haemoglobin A1c. The company maintains a significant international presence, serving clinical laboratories and point-of-care segments across more than 75 countries. Following the strategic acquisition of biosensor assets from Waveform Technologies Inc., Trinity Biotech has successfully diversified its operational focus to include wearable biosensors, positioning itself as a key player in the rapidly evolving digital health and diabetes management landscape.
How much funding has Trinity Biotech raised?
Trinity Biotech has raised a total of $211.5M across 7 funding rounds:
Debt
$115M
Corporate Investment
$45M
Debt
$5M
Other Financing Round
$5.5M
Debt
$4M
Debt
$5M
Unspecified
$25M
Debt (2015): $115M with participation from Undisclosed
Corporate Investment (2022): $45M led by MiCo
Debt (2023): $5M, investors not publicly disclosed
Other Financing Round (2024): $5.5M, investors not publicly disclosed
Debt (2025): $4M backed by Perceptive Advisors
Debt (2025): $5M with participation from Perceptive Advisors
Unspecified (2026): $25M led by Yorkville Advisors
Key Investors in Trinity Biotech
Yorkville Advisors
Yorkville Advisors is a global investment manager that specializes in providing flexible debt and equity financing solutions for public and private companies worldwide, focusing on supporting growth and long-term success.
Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment firm managing around $7 billion in assets, focused on funding innovative healthcare and life sciences technologies.
MiCo
MiCo is a strategic corporate investor with a focus on advanced technology sectors, providing capital and industrial expertise to support the scaling of innovative diagnostic and biosensor platforms.
What's next for Trinity Biotech?
With the recent influx of capital, Trinity Biotech is poised to prioritize the development and market penetration of its continuous glucose monitoring (CGM) product line. The strategic roadmap likely involves scaling manufacturing capabilities to meet international demand while simultaneously refining its biosensor technology to enhance diagnostic accuracy and user experience. As the company navigates this growth phase, the focus will remain on integrating its wearable solutions into existing clinical workflows, thereby strengthening its competitive advantage in the global diagnostics market. Investors will be closely monitoring the company's ability to translate this recent financing into sustained revenue growth and expanded market share in the high-stakes diabetes management sector.
See full Trinity Biotech company page
